Yubo International Biotech LTD 10-Q quarterly reports

Yubo International Biotech Limited filed its Q2 2026 Form 10-Q, reporting zero revenue for the period and continued net losses, raising substantial doubt about its going concern status.

Yubo International Biotech reported zero revenue and a net loss of $295,026 for the first quarter of 2026, citing ongoing market research and evaluation.

Yubo International Biotech Limited reported zero revenue for the nine months ended September 30, 2025, alongside a significant net loss and a going concern warning.

Yubo International Biotech Limited reported no sales for the first half of 2025, alongside continued significant net losses and a going concern warning.

Yubo International Biotech reports zero revenue for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Yubo International Biotech's Q3 2024 results show a significant decrease in revenue and an increase in operating expenses, leading to a net loss.

Yubo International Biotech's Q2 2024 results reveal a significant decrease in revenue and increased operating expenses, leading to a larger net loss compared to the same period last year.

Yubo International Biotech's Q1 2024 results show a significant decrease in revenue and an increase in operating expenses, leading to a larger net loss compared to the same period last year.